share_log

Don't Ignore The Insider Selling In Pacific Biosciences of California

Don't Ignore The Insider Selling In Pacific Biosciences of California

不要忽视加州太平洋生物科学的内幕销售
Simply Wall St ·  01/15 14:15

Anyone interested in Pacific Biosciences of California, Inc. (NASDAQ:PACB) should probably be aware that the Chief Operating Officer, Mark Van Oene, recently divested US$241k worth of shares in the company, at an average price of US$7.77 each. The eyebrow raising move amounted to a reduction of 12% in their holding.

任何对加州太平洋生物科学公司(纳斯达克股票代码:PACB)感兴趣的人都应该知道,首席运营官马克·范·奥恩最近以每股7.77美元的平均价格剥离了该公司价值24.1万美元的股份。此次举措使他们的持股量减少了12%。

See our latest analysis for Pacific Biosciences of California

查看我们对加州太平洋生物科学公司的最新分析

Pacific Biosciences of California Insider Transactions Over The Last Year

加州太平洋生物科学公司去年内幕交易

In the last twelve months, the biggest single sale by an insider was when the President, Christian O. Henry, sold US$980k worth of shares at a price of US$10.12 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The good news is that this large sale was at well above current price of US$6.71. So it is hard to draw any strong conclusion from it.

在过去的十二个月中,内部人士最大的一次出售是总裁克里斯蒂安·奥·亨利以每股10.12美元的价格出售了价值9.8万美元的股票。我们通常不喜欢看到内幕销售,但是销售价格越低,我们就越担心。好消息是,此次大宗销售远高于当前6.71美元的价格。因此,很难从中得出任何强有力的结论。

Insiders in Pacific Biosciences of California didn't buy any shares in the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

加州太平洋生物科学公司的内部人士去年没有购买任何股票。你可以在下面看到过去 12 个月的内幕交易(公司和个人)的直观描述。如果你想确切地知道谁卖了、卖了多少以及何时出售,只需点击下图!

insider-trading-volume
NasdaqGS:PACB Insider Trading Volume January 15th 2024
纳斯达克股票代码:PACB 内幕交易量 2024 年 1 月 15 日

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

如果你像我一样,那么你不会想错过这份业内人士正在收购的成长型公司的免费名单。

Insider Ownership Of Pacific Biosciences of California

加州太平洋生物科学公司的内部所有权

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that Pacific Biosciences of California insiders own 0.3% of the company, worth about US$5.5m. We do generally prefer see higher levels of insider ownership.

许多投资者喜欢查看公司内部人士拥有多少股份。较高的内部所有权通常会使公司领导层更加关注股东的利益。从我们的数据来看,加州太平洋生物科学公司的内部人士似乎拥有该公司0.3%的股份,价值约550万美元。我们通常更愿意看到更高的内部所有权水平。

So What Does This Data Suggest About Pacific Biosciences of California Insiders?

那么,这些数据对加州内部人士的太平洋生物科学有何启示呢?

An insider sold Pacific Biosciences of California shares recently, but they didn't buy any. And there weren't any purchases to give us comfort, over the last year. When you consider that most companies have higher levels of insider ownership, we're a little wary. So we'd only buy after very careful consideration. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 4 warning signs for Pacific Biosciences of California you should know about.

一位内部人士最近出售了加利福尼亚太平洋生物科学公司的股票,但他们没有购买任何股票。在过去的一年里,没有任何能让我们感到安慰的购买。当你考虑到大多数公司的内部所有权水平更高时,我们有点警惕。因此,我们只有在经过仔细考虑后才会购买。虽然我们喜欢了解内部人士的所有权和交易情况,但在做出任何投资决策之前,我们一定要考虑股票面临的风险。每家公司都有风险,我们发现了你应该知道的加利福尼亚太平洋生物科学公司的4个警告信号。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

当然,通过寻找其他地方,你可能会找到一笔不错的投资。因此,来看看这份有趣的公司的免费清单吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,内部人士是那些向相关监管机构报告交易的个人。我们目前仅对公开市场交易和直接权益的私人处置进行核算,但不包括衍生品交易或间接权益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发